Few studies have described the relationship between both CSF p-tau and [18F]flortaucipir binding with proxies of disease severity, and it remains to be established whether [18F]flortaucipir PET and p-tau can be viewed as equivalent markers for AD staging. The gene discussed is MAPT; the disease is Alzheimer disease.